190 related articles for article (PubMed ID: 18245529)
21. Mechanical regulation of the Cyr61/CCN1 and CTGF/CCN2 proteins.
Chaqour B; Goppelt-Struebe M
FEBS J; 2006 Aug; 273(16):3639-49. PubMed ID: 16856934
[TBL] [Abstract][Full Text] [Related]
22. The CCN3 gene coding for an extracellular adhesion-related protein is transcriptionally activated by the p53 tumor suppressor.
Böhlig L; Metzger R; Rother K; Till H; Engeland K
Cell Cycle; 2008 May; 7(9):1254-61. PubMed ID: 18418052
[TBL] [Abstract][Full Text] [Related]
23. CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family.
Lin CG; Leu SJ; Chen N; Tebeau CM; Lin SX; Yeung CY; Lau LF
J Biol Chem; 2003 Jun; 278(26):24200-8. PubMed ID: 12695522
[TBL] [Abstract][Full Text] [Related]
24. CCN3/NOV inhibits BMP-2-induced osteoblast differentiation by interacting with BMP and Notch signaling pathways.
Minamizato T; Sakamoto K; Liu T; Kokubo H; Katsube K; Perbal B; Nakamura S; Yamaguchi A
Biochem Biophys Res Commun; 2007 Mar; 354(2):567-73. PubMed ID: 17250806
[TBL] [Abstract][Full Text] [Related]
25. CCNs, fibulin-1C and S100A4 expression in leiomyoma and myometrium: inverse association with TGF-beta and regulation by TGF-beta in leiomyoma and myometrial smooth muscle cells.
Luo X; Ding L; Chegini N
Mol Hum Reprod; 2006 Apr; 12(4):245-56. PubMed ID: 16571622
[TBL] [Abstract][Full Text] [Related]
26. CCN3 Proteins as a diagnostic marker in osteosarcoma patients: A case control study.
Siddiqui S; Pandey V; Ali S; Singh A; Sharma D; Yadav M; Raikwar A
Cancer Treat Res Commun; 2021; 28():100381. PubMed ID: 33946014
[TBL] [Abstract][Full Text] [Related]
27. Urinary mRNA expression of CCN2/CCN3 as a noninvasive marker for monitoring glomerular structure changes in nondiabetic chronic kidney disease.
Chen L; Wu YG; Liu D; Lv LL; Zheng M; Ni HF; Cao YH; Liu H; Zhang P; Zhang JD; Liu BC
Biomarkers; 2012 Dec; 17(8):714-20. PubMed ID: 23061738
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effect of CT domain of CCN3/NOV on proliferation and differentiation of osteogenic mesenchymal stem cells, Kusa-A1.
Katsuki Y; Sakamoto K; Minamizato T; Makino H; Umezawa A; Ikeda MA; Perbal B; Amagasa T; Yamaguchi A; Katsube K
Biochem Biophys Res Commun; 2008 Apr; 368(3):808-14. PubMed ID: 18275847
[TBL] [Abstract][Full Text] [Related]
29. The CCN3 (NOV) cell growth regulator: a new tool for molecular medicine.
Perbal B
Expert Rev Mol Diagn; 2003 Sep; 3(5):597-604. PubMed ID: 14510180
[TBL] [Abstract][Full Text] [Related]
30. In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type.
Benini S; Perbal B; Zambelli D; Colombo MP; Manara MC; Serra M; Parenza M; Martinez V; Picci P; Scotlandi K
Oncogene; 2005 Jun; 24(27):4349-61. PubMed ID: 15824736
[TBL] [Abstract][Full Text] [Related]
31. CCN1 (CYR61) and CCN3 (NOV) signaling drives human trophoblast cells into senescence and stimulates migration properties.
Kipkeew F; Kirsch M; Klein D; Wuelling M; Winterhager E; Gellhaus A
Cell Adh Migr; 2016 Mar; 10(1-2):163-78. PubMed ID: 26744771
[TBL] [Abstract][Full Text] [Related]
32. Prognostic relevance of CCN3 in Ewing sarcoma.
Perbal B; Lazar N; Zambelli D; Lopez-Guerrero JA; Llombart-Bosch A; Scotlandi K; Picci P
Hum Pathol; 2009 Oct; 40(10):1479-86. PubMed ID: 19695675
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of CCN3 expression as a potential mechanism for melanoma progression.
Fukunaga-Kalabis M; Martinez G; Telson SM; Liu ZJ; Balint K; Juhasz I; Elder DE; Perbal B; Herlyn M
Oncogene; 2008 Apr; 27(18):2552-60. PubMed ID: 17968313
[TBL] [Abstract][Full Text] [Related]
34. Establishment, characterisation and partial cytokine expression profile of a new human osteosarcoma cell line (CAL 72).
Rochet N; Dubousset J; Mazeau C; Zanghellini E; Farges MF; de Novion HS; Chompret A; Delpech B; Cattan N; Frenay M; Gioanni J
Int J Cancer; 1999 Jul; 82(2):282-5. PubMed ID: 10389764
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer-secreted CCN3 uses the GSK3β and β-catenin pathways to enhance osteogenic factor levels in osteoblasts.
Chen PC; Liu SC; Lin TH; Lin LW; Wu HC; Tai HC; Wang SW; Tang CH
Environ Toxicol; 2021 Mar; 36(3):425-432. PubMed ID: 33107671
[TBL] [Abstract][Full Text] [Related]
36. CCN2 promotes drug resistance in osteosarcoma by enhancing ABCG2 expression.
Tsai HC; Chang AC; Tsai CH; Huang YL; Gan L; Chen CK; Liu SC; Huang TY; Fong YC; Tang CH
J Cell Physiol; 2019 Jun; 234(6):9297-9307. PubMed ID: 30317661
[TBL] [Abstract][Full Text] [Related]
37. The CCN3 protein and cancer.
Perbal B
Adv Exp Med Biol; 2006; 587():23-40. PubMed ID: 17163153
[TBL] [Abstract][Full Text] [Related]
38. Antiproliferative activity of CCN3: involvement of the C-terminal module and post-translational regulation.
Bleau AM; Planque N; Lazar N; Zambelli D; Ori A; Quan T; Fisher G; Scotlandi K; Perbal B
J Cell Biochem; 2007 Aug; 101(6):1475-91. PubMed ID: 17340618
[TBL] [Abstract][Full Text] [Related]
39. Expression of connective tissue growth factor (CTGF/CCN2) in head and neck squamous cell carcinoma.
Mullis TC; Tang X; Chong KT
J Clin Pathol; 2008 May; 61(5):606-10. PubMed ID: 18441156
[TBL] [Abstract][Full Text] [Related]
40. Serum microRNA-221 functions as a potential diagnostic and prognostic marker for patients with osteosarcoma.
Yang Z; Zhang Y; Zhang X; Zhang M; Liu H; Zhang S; Qi B; Sun X
Biomed Pharmacother; 2015 Oct; 75():153-8. PubMed ID: 26422796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
